GlassScriptPhysician profile
James B Walsh
NPI 1619970340
$9,159.59
in general payments reported to CMS, 2019-2025
47 companies · $1,065 in 2025
The $1,065 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,214 · 2020: $656 · 2021: $1,887 · 2022: $1,582 · 2023: $1,243 · 2024: $1,511 · 2025: $1,065.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,819.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,819.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,037.50 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $996.63 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $765.10 | 2020-2025 | Vraylar, Synthroid |
| Lilly USA, LLC | $593.06 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Merck Sharp & Dohme LLC | $509.32 | 2020-2025 | Verquvo, Steglatro, Belsomra |
| Pfizer INC. | $477.80 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $421.38 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Janssen Pharmaceuticals, INC | $381.81 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $372.69 | 2023-2025 | Rexulti |
| Exact Sciences Corporation | $326.64 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amgen INC. | $325.34 | 2022-2024 | Repatha, Otezla, Prolia |
| Astellas Pharma US INC | $271.01 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $223.17 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $164.88 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $162.12 | 2022-2024 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Walsh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.